SpringWorks Therapeutics is a biomedical company that focuses on acquiring, developing, and marketing drugs to treat patients with rare diseases and cancer. Among its products, nirogacestat is currently in Phase III clinical trial for the treatment of desmoid tumors, while mirdametinib is in Phase 2b clinical trial for neurofibromatosis. The company has several partnerships and collaborations in the field, and is based in Connecticut.